Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway

Lu Jiang1,2, Ying-Jian Sun3, Xiao-Hua Song1

  • 1Laboratory of Molecular Toxicology, Institute of Zoology, State Key Laboratory of Integrated Management of Pest Insects and Rodents, Chinese Academy of Sciences Beijing 100101, China.

Insights

Ivermectin (IVM), an antiparasitic drug, effectively inhibits cancer cell migration and metastasis in preclinical models. This study supports exploring IVM for anti-metastasis cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Tumor metastasis is a primary driver of cancer-related mortality.
  • Effective anti-metastasis therapies are crucial for improving patient outcomes.
  • Ivermectin (IVM), an FDA-approved antiparasitic, is explored for novel therapeutic applications.

Purpose of the Study:

  • To investigate the potential of ivermectin (IVM) as an anti-metastasis agent.
  • To evaluate the efficacy of IVM in inhibiting cancer cell motility and tumor metastasis.
  • To elucidate the molecular mechanisms underlying IVM's anti-metastatic effects.

Main Methods:

  • Utilized colorectal and breast cancer cell lines for in vitro studies.
  • Employed a xenograft tumor metastasis model for in vivo evaluation.
  • Analyzed the expression of migration-related proteins and signaling pathways.

Main Results:

  • Ivermectin significantly inhibited cancer cell motility in vitro.
  • IVM demonstrated significant suppression of tumor metastasis in vivo.
  • Mechanistically, IVM suppressed Wnt/β-catenin/integrin β1/FAK signaling pathways.

Conclusions:

  • Ivermectin exhibits potent anti-metastatic properties in preclinical cancer models.
  • IVM's mechanism involves the inhibition of key migration-related signaling cascades.
  • These findings provide a strong rationale for investigating IVM in clinical settings for cancer metastasis prevention and treatment.

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.8K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.8K